Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 247 clinical trials
Covid-19 Vaccination in Adolescents

immunosorbent assay, plaque reduction neutralization assay, luciferase immunoprecipitation system assay and flow cytometry. Interventions BNT162b2, CoronaVac and AZD1222. Main outcome measures

  • 21 Apr, 2021
  • 1 location
Elotuzumab in Combination With Carfilzomib Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III trials in MM patients. One phase III trial in MM patients with one to three prior lines of therapy compared elotuzumab-Rd with standard Rd. …

  • 03 Mar, 2021
  • 58 locations
AGA Biocellular Stem/Stromal Hair Regenerative Study

Centricyte 1000 system for cellular isolation of AD-cSVF from AD-tSVF and testing by Flow Cytometry (ORFLO MoxiFlow) Procedure: Closed syringe microcannula lipoaspiration (AD-tSVF) Procedure: Emulsification

  • 28 Jan, 2021
  • 1 location
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

risk for early relapse. Tests for HCL MRD in blood or marrow include flow cytometry (FACS) or PCR using consensus primers. The most sensitive HCL MRD test is real-time quantitative PCR using sequence

  • 13 Jun, 2021
  • 1 location
Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia

Usually Chronic lymphocytic leukemia (CLL) is a disease of the elderly patients. However, the diagnosis in young patients become more frequently with poor prognosis. The identification of new prognostic factors permits early determination of the high risk population and provide them the therapeutic intensification. Allogeneic transplantation of hematopoietic stem cells …

cell transplantation
graft versus host disease
lymphoid leukemia
  • 07 Nov, 2020
  • 1 location
Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML

Great progress has been witnessed on the treatment of acute myeloid leukemia (AML) in recent years. However, elderly patients ineligible for receiving high dose chemotherapy and allo-HSCT, have high relapse rate and treatment-related complications. Azacitidine (AZA), a listed hypomethylating agent in China in 2018, is the only approved demethylating drug …

  • 25 Jan, 2021
  • 2 locations
Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients

About one third of prospective kidney transplant recipients have antibodies in their blood directed against the tissues of their only available kidney donor. Recently, "desensitisation" treatments when administered pre-transplant have allowed successful transplantation of these patients despite high rates of acute antibody mediated rejection (AAMR). The investigators propose to test …

  • 07 Nov, 2020
  • 3 locations
Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids

Background The immune system defends the body against bacteria and other harmful invaders. But it can overact and attack healthy cells by mistake. The group of drugs called glucocorticoids (GCs) can calm down an overactive immune system. But they often cause negative side effects. Researchers want to learn how human …

  • 29 Apr, 2021
  • 1 location
Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma

This is a single arm, single site, feasibility study of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) to promote immunotherapy responses in patients with undifferentiated pleomorphic sarcoma

  • 03 Jun, 2021
  • 1 location
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.

  • 26 Jan, 2021
  • 6 locations